Collaborative arrangements cost sharing payments.

No definition available.

Name:	akba_CollaborativeArrangementsCostSharingPayments
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Contract with Customer, Non-Cash Revenue Recognized

+ References

No definition available.

+ Details

Name:	akba_ContractWithCustomerNonCashRevenueRecognized
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cost share costs incurred by partner for license agreement.

+ References

No definition available.

+ Details

Name:	akba_CostShareCostsIncurredByPartnerForLicenseAgreement
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cost share costs incurred for license agreement.

+ References

No definition available.

+ Details

Name:	akba_CostShareCostsIncurredForLicenseAgreement
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of performance obligations.

+ References

No definition available.

+ Details

Name:	akba_NumberOfPerformanceObligations
Namespace Prefix:	akba_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Payment for license agreement reimbursement of costs incurred.

+ References

No definition available.

+ Details

Name:	akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payment receivable for license agreement reimbursement of previously costs incurred.

+ References

No definition available.

+ Details

Name:	akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payment received for license agreement reimbursement of costs incurred.

+ References

No definition available.

+ Details

Name:	akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue from Contracts with Customers, Percentage of Costs Funded by Customer

+ References

No definition available.

+ Details

Name:	akba_RevenueFromContractsWithCustomersPercentageOfCostsFundedByCustomer
Namespace Prefix:	akba_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Upfront cash payment received.

+ References

No definition available.

+ Details

Name:	akba_UpfrontCashPaymentReceived
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeUnitedStatesAndInternationalCollaborationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContractWithCustomerBasisOfPricingAxis=akba_UpFrontNonRefundableAndNonCreditableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License, Collaboration and Other Significant Agreements - U.S. Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. Narrative (Details) $ in Thousands		1 Months Ended	12 Months Ended
	Dec. 31, 2016 USD ($)	Jul. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) performance_obligation	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Apr. 01, 2019	Mar. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues			$ 292,484	$ 211,650	$ 294,644
Revenue recognized			29,574	23,364	36,032
Non-cash collaboration revenue			9,550	0	0
License, collaboration and other revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues			$ 115,535	71,362	166,406
Otsuka Pharmaceutical Co. Ltd. \| Otsuka U.S. Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of performance obligations \| performance_obligation			3
Percentage of costs funded by customer						80.00%	52.50%
Reimbursement for counterparty share of costs previously incurred	$ 33,800
Collaborative arrangements cost sharing payments			$ 319,200
Cumulative catch-up adjustment to revenue, modification of contract		$ 55,000
Revenue recognized			15,500
Non-cash collaboration revenue			9,600
Cost share costs incurred			7,600	17,500	5,100
Reimbursable by Otsuka			3,800	8,600	2,200
Cost share costs by partner for license agreement			0	900	2,100
Reimbursable to Otsuka				400	1,100
Otsuka Pharmaceutical Co. Ltd. \| Otsuka U.S. Agreement \| License, collaboration and other revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues			86,773	$ 36,588	$ 93,446
Otsuka Pharmaceutical Co. Ltd. \| Development and Commercialize United States and International Collaboration and License Agreement \| License, collaboration and other revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues			92,300
Otsuka Pharmaceutical Co. Ltd. \| Up-front, Non-refundable and Non-creditable \| Otsuka U.S. Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront cash payment received			$ 125,000